Realchemie Schwefel-II

Hauptinformation

  • Handelsname:
  • Realchemie Schwefel-II
  • Verwenden für:
  • Pflanzen
  • Art der Medizin:
  • Agrochemisch

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Realchemie Schwefel-II
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Akarizid Fungizid

Weitere Informationen

Status

  • Quelle:
  • UFAG - Ufficio federale dell'agricoltura. OFAG - Office fédéral de l'agriculture. BLW - Bundesamt für Landwirtschaft.
  • Zulassungsnummer:
  • D-5800
  • Letzte Änderung:
  • 06-09-2017

Packungsbeilage

Produkt:

Handelsbezeichnung: Realchemie Schwefel-II (Parallelimport)

Produktekategorie

Ausl. Bewilligungsinhaber

Eidg. Zulassungsnummer

Akarizid

Fungizid

Realchemie Nederland B.V.

D-5800

Packungsbeilagenummer Herkunftsland

Ausl. Zulassungsnummer

4571

Deutschland

GP 052273-00/003

Stoff(e)

Gehalt

Formulierungscode

Wirkstoff: Schwefel

80 %

WG Wasserdispergierbares Granulat

Anwendungen

A Kultur

Schaderreger/Wirkung Dosierungshinweise

Auflagen

B Brombeere

Gallmilben

Konzentration: 1 %

Aufwandmenge: 10 kg/ha

Anwendung: Nach Austrieb, bei

Trieblänge 10-15 cm.

1, 2, 3

B Brombeere

Gallmilben

Konzentration: 2 %

Aufwandmenge: 20 kg/ha

Anwendung: Austriebsspritzung.

2, 3

B Erdbeere

Echter Mehltau der

Erdbeere

Konzentration: 0.2 - 0.4 %

Aufwandmenge: 2 - 4 kg/ha

3, 4, 5

O Kernobst

Echter Mehltau des

Apfels/der Birne

Teilwirkung:

Schorf des Kernobstes

Nebenwirkung:

Rostmilben

Konzentration: 0.3 - 0.5 %

Aufwandmenge: 4.8 - 8 kg/ha

Anwendung: Nach der Blüte.

3, 6, 7

O Kernobst

Echter Mehltau des

Apfels/der Birne

Teilwirkung:

Konzentration: 0.5 - 0.75 %

Aufwandmenge: 8 - 12 kg/ha

3, 7

A Kultur

Schaderreger/Wirkung Dosierungshinweise

Auflagen

Schorf des Kernobstes

Nebenwirkung:

Rostmilben

Anwendung: Vor der Blüte.

O Kernobst

Echter Mehltau des

Apfels/der Birne

Teilwirkung:

Schorf des Kernobstes

Nebenwirkung:

Rostmilben

Konzentration: 0.75 %

Aufwandmenge: 12 kg/ha

Anwendung: Beim Austrieb.

3, 7

O Pfirsich / Nektarine

Echter Mehltau des

Pfirsichs

Schorf des Pfirsichs

Konzentration: 0.3 - 0.5 %

Aufwandmenge: 4.8 - 8 kg/ha

Wartefrist: 3 Woche(n)

Anwendung: Nach der Blüte.

3, 7

O Steinobst

Schrotschuss

Nebenwirkung:

Rostmilben

Konzentration: 0.75 %

Aufwandmenge: 12 kg/ha

Anwendung: Vor der Blüte.

3, 7, 8

O Steinobst

Schrotschuss

Nebenwirkung:

Rostmilben

Konzentration: 0.3 - 0.5 %

Aufwandmenge: 4.8 - 8 kg/ha

Wartefrist: 3 Woche(n)

Anwendung: Nach der Blüte.

3, 7, 8

W Reben

Echter Mehltau der

Rebe

Konzentration: 0.1 - 0.4 %

Aufwandmenge: 1.6 - 6.4 kg/ha

Wartefrist: 3 Woche(n)

Anwendung: Vor- und

Nachblütebehandlungen bis spätestens

Mitte August.

3, 9, 10,

W Reben

Kräuselmilbe

Pockenmilbe der Reben

Konzentration: 2 %

Aufwandmenge: 16 kg/ha

Anwendung: Austriebsspritzung.

3, 12

Kürbisgewächse

(Cucurbitaceae)

Echter Mehltau der

Kürbisgewächse

Konzentration: 0.1 - 0.2 %

Aufwandmenge: 1 - 2 kg/ha

Wartefrist: 3 Tage

G Tomaten

Echter Mehltau der

Tomate

Konzentration: 0.1 - 0.2 %

Wartefrist: 3 Tage

Hopfen

Echter Mehltau des

Hopfens

Konzentration: 0.25 %

Wartefrist: 1 Woche(n)

Anwendung: Vorbeugend ab 1 m

Wuchshöhe.

3, 13

Bäume und Sträucher

(ausserhalb Forst)

Blumenkulturen und

Grünpflanzen

Rosen

Echte Mehltaupilze der

Zierpflanzen

Konzentration: 0.1 - 0.2 %

A Kultur

Schaderreger/Wirkung Dosierungshinweise

Auflagen

Z Kirschlorbeer

Schrotschuss

Konzentration: 0.1 - 0.2 %

Auflagen und Bemerkungen:

Bei stärkerem Befall zweite Behandlung.

Für Brombeeren bezieht sich die angegebene Aufwandmenge auf Stadium "Erste Blüten bis etwa

50% der Blüten offen" sowie eine Referenzbrühmenge von 1000 l/ha.

Ansetzen der Spritzbrühe: Schutzhandschuhe tragen.

Keine Behandlung von der Blüte bis zum Ende der Ernte.

Die angegebene Aufwandmenge bezieht sich auf Stadium "Vollblüte bis Beginn Rotfärbung der

Früchte", 4 Pflanzen pro m² sowie eine Referenzbrühmenge von 1000 l/ha.

Nachblütebehandlungen nur bei schwefelverträglichen Sorten.

Die angegebene Aufwandmenge bezieht sich auf ein Baumvolumen von 10'000 m³ pro ha.

Aprikosen sind schwefelempfindlich, keine Behandlungen.

Auch für die Luftapplikation.

10.Die angegebene Aufwandmenge bezieht sich auf Stadium BBCH 71-81 (J-M, Nachblüte) und

eine Referenzbrühemenge von 1600 l/ha (Berechnungsgrundlage) oder auf ein Laubwandvolumen

von 4500 m³ pro ha.

11.Höhere Aufwandmengen bei starkem Befallsdruck.

12.Die angegebene Aufwandmenge bezieht sich auf Stadium BBCH 15-51 (F) und eine

Referenzbrühmenge von 800 l/ha (Berechnungsgrundlage).

13.Maximal 15 Behandlungen im Abstand von ca. 7 Tagen pro Parzelle und Jahr.

Gefahrenkennzeichnungen:

Es gilt die Einstufung und Kennzeichnung der ausländischen Originaletikette.

Zusätzliche Schweizerische Gefahrenkennzeichnungen:

SP 1 Mittel und/oder dessen Behälter nicht in Gewässer gelangen lassen.

Im Zweifelsfall gelten einzig die Originaldokumente der Zulassung. Die Erwähnung eines Produktes,

Wirkstoffes oder einer Firma stellt keine Empfehlung dar und bedeutet nicht, dass sich das Produkt im

Verkauf befindet.

18-10-2018

Flushmate recalls Flushmate II 501-B Pressure-Assisted Flushing Systems

Flushmate recalls Flushmate II 501-B Pressure-Assisted Flushing Systems

The Flushmate II 501-B system can burst at or near the vessel weld seam releasing stored pressure. This pressure can lift the tank lid and shatter the tank, posing impact and laceration hazards to consumers and property damage.

Health Canada

17-10-2018

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Lumpy skin disease: scientific and technical assistance on control and surveillance activities

Published on: Tue, 16 Oct 2018 00:00:00 +0200 The duration of the vaccination campaign sufficient to eliminate lumpy skin disease (LSD) mainly depends on the vaccination effectiveness and coverage achieved. By using a spread epidemiological model, assuming a vaccination effectiveness of 65%, with 50% and 90% coverage, 3 and 4 years campaigns, respectively, are needed to eliminate LSD. When vaccination effectiveness is 80% to 95%, 2 years of vaccination at coverage of 90% is sufficient to eliminate LSD vir...

Europe - EFSA - European Food Safety Authority Publications

27-9-2018

Outcome of the consultation on confirmatory data used in risk assessment for the active substance  copper (I), copper (II) variants

Outcome of the consultation on confirmatory data used in risk assessment for the active substance copper (I), copper (II) variants

Published on: Wed, 26 Sep 2018 00:00:00 +0200 The European Food Safety Authority (EFSA) was asked by the European Commission to provide scientific assistance with respect to the risk assessment for an active substance in light of confirmatory data requested following the first approval in accordance with Article 6(1) of Directive 91/414/EEC and Article 6(f) of Regulation (EC) No 1107/2009. In this context EFSA's scientific views on the specific points raised during the commenting phase conducted with Me...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Identification and evaluation of potentially mutagenic and carcinogenic food contaminants

Identification and evaluation of potentially mutagenic and carcinogenic food contaminants

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Heat processing of food gives rise to a plethora of chemical compounds whose toxicological effects are largely unknown. Due to a general lack of experimental toxicological data, assessing the risks associated with the consumption of these substances remains a challenge. Computer models that allow for an in silico prediction of physicochemical and toxicological characteristics, may be able to fill current data gaps and facilitate the risk assessment of toxico...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms

Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms

Published on: Thu, 23 Aug 2018 00:00:00 +0200 Following a request from EFSA, the Panel on Plant Protection Products and their Residues (PPR) developed an opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) models and their use in prospective environmental risk assessment (ERA) for pesticides and aquatic organisms. TKTD models are species‐ and compound‐specific and can be used to predict (sub)lethal effects of pesticides under untested (time‐variable) exposure conditions. Three differen...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Published on: Tue, 21 Aug 2018 00:00:00 +0200 Abstract In May 2018, EFSA and ECDC co‐facilitated a workshop on preparedness for a multi‐national food safety/public health incident. The workshop, hosted at AGES in Vienna, was conceived to closely align with EFSA's Strategy 2020 commitment to prepare for future risk assessment challenges. EFSA, ECDC, AGES and BfR worked together closely to develop a workshop and associated training materials to be delivered over a 2.5‐day agenda. The workshop was attended...

Europe - EFSA - European Food Safety Authority Publications

9-8-2018

Dringende Sicherheitsinformation zu GENESIS II NON POROUS C/R FEMORAL SIZE 6 RIGHT von Smith & Nephew Orthopaedics GmbH

Dringende Sicherheitsinformation zu GENESIS II NON POROUS C/R FEMORAL SIZE 6 RIGHT von Smith & Nephew Orthopaedics GmbH

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

14-7-2018

Dringende Sicherheitsinformation zu Vitamin D total II, Elecsys Vitamin D total II von Roche Diagnostics GmbH

Dringende Sicherheitsinformation zu Vitamin D total II, Elecsys Vitamin D total II von Roche Diagnostics GmbH

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

5-7-2018

Dringende Sicherheitsinformation zu VISERA ELITE II VIDEO SYSTEM CENTER  OLYMPUS von Olympus Medical Systems Corp.

Dringende Sicherheitsinformation zu VISERA ELITE II VIDEO SYSTEM CENTER OLYMPUS von Olympus Medical Systems Corp.

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

4-7-2018

Addendum I und II

Addendum I und II

Addendum I und II

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

23-6-2018

Dringende Sicherheitsinformation zu MRSASelect II von Bio-Rad Laboratories France

Dringende Sicherheitsinformation zu MRSASelect II von Bio-Rad Laboratories France

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

31-5-2018

Dringende Sicherheitsinformation zu Hüftpfanne Müller II von OHST Medizintechnik AG

Dringende Sicherheitsinformation zu Hüftpfanne Müller II von OHST Medizintechnik AG

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

14-6-2010

Change of the reimbursement for certain cardiovascular products as of 15 November 2010

Change of the reimbursement for certain cardiovascular products as of 15 November 2010

The Reimbursement Committee and the Danish Medicines Agency have reviewed some of the medicinal products used for the treatment of cardiovascular disease (antihypertensives) in order to assess whether they meet the criteria for public reimbursement. The medicinal products concerned are the so-called angiotensin II antagonists and renin inhibitors.

Danish Medicines Agency

3-6-2010

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

Consultation responses on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors)

The Reimbursement Committee’s recommendation concerning the future reimbursement status of medicinal products in ATC groups C09C, C09D and C09X (angiotensin II antagonists and renin inhibitors) was open for consultation until 7 May 2010.

Danish Medicines Agency

21-4-2010

Decision on future reimbursement status of losartan-containing medicines (C09CA01 and C09DA01) - angiotensin II antagonists

Decision on future reimbursement status of losartan-containing medicines (C09CA01 and C09DA01) - angiotensin II antagonists

On 16 April 2010, the Danish Medicines Agency decided on the future reimbursement status of some of the losartan-containing medicines in ATC groups C09C and C09D, making these products eligible for general reimbursement as of 19 April 2010.

Danish Medicines Agency

14-9-2018

#FDA MQSA: Mammography Facility Adverse Event and Action Report - September 13, 2018: Lakes Radiology II, Inc. Read the report here:  http://go.usa.gov/xPgTB  #MedicalDevice

#FDA MQSA: Mammography Facility Adverse Event and Action Report - September 13, 2018: Lakes Radiology II, Inc. Read the report here: http://go.usa.gov/xPgTB  #MedicalDevice

#FDA MQSA: Mammography Facility Adverse Event and Action Report - September 13, 2018: Lakes Radiology II, Inc. Read the report here: http://go.usa.gov/xPgTB  #MedicalDevice

FDA - U.S. Food and Drug Administration

7-9-2018

 2018 Annual workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), European Medicines Agency, London, UK, From: 07-Jun-2018, To: 07-Jun-2018

2018 Annual workshop of the European Network of Paediatric Research at the European Medicines Agency (Enpr-EMA), European Medicines Agency, London, UK, From: 07-Jun-2018, To: 07-Jun-2018

Enpr-EMA will hold its tenth annual workshop on 7-8 June 2018 at EMA. The workshop brings relevant stakeholders together to discuss requirements, barriers and opportunities for the conduct of high-quality clinical studies in children. The overall theme of this year’s workshop will be a ‘holistic approach to paediatric research’. Highlights of this year’s workshop include: i) short perspectives of the various stakeholders involved in paediatric research (patient/young people advisory groups, research netw...

Europe - EMA - European Medicines Agency

4-9-2018

Epoetin alfa Hexal (Hexal AG)

Epoetin alfa Hexal (Hexal AG)

Epoetin alfa Hexal (Active substance: epoetin alfa) - Centralised - 2-Monthly update - Commission Decision (2018)5857 of Tue, 04 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/726/II/WS/1406

Europe -DG Health and Food Safety

4-9-2018

Binocrit (Sandoz GmbH)

Binocrit (Sandoz GmbH)

Binocrit (Active substance: epoetin alfa) - Centralised - 2-Monthly update - Commission Decision (2018)5856 of Tue, 04 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/725/II/WS/1406

Europe -DG Health and Food Safety

4-9-2018

Spinraza (Biogen Idec Limited)

Spinraza (Biogen Idec Limited)

Spinraza (Active substance: nusinersen) - Centralised - 2-Monthly update - Commission Decision (2018)5862 of Tue, 04 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4312/II/4

Europe -DG Health and Food Safety

3-9-2018

Apis/Levisticum II

Rote - Liste

30-8-2018

Fluenz Tetra (AstraZeneca AB)

Fluenz Tetra (AstraZeneca AB)

Fluenz Tetra (Active substance: influenza vaccine (live attenuated, nasal)) - Centralised - Variation - Commission Decision (2018)5815 of Thu, 30 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2617/II/82

Europe -DG Health and Food Safety

29-8-2018

Coagadex (Bio Products Laboratory Ltd)

Coagadex (Bio Products Laboratory Ltd)

Coagadex (Active substance: human coagulation factor X) - Centralised - 2-Monthly update - Commission Decision (2018)5772 of Wed, 29 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3855/II/07

Europe -DG Health and Food Safety

29-8-2018

Nucala (GlaxoSmithKline Trading Services Limited)

Nucala (GlaxoSmithKline Trading Services Limited)

Nucala (Active substance: mepolizumab) - Centralised - 2-Monthly update - Commission Decision (2018)5770 of Wed, 29 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3860/II/13/G

Europe -DG Health and Food Safety

27-8-2018

RoActemra (Roche Registration GmbH)

RoActemra (Roche Registration GmbH)

RoActemra (Active substance: tocilizumab) - Centralised - 2-Monthly update - Commission Decision (2018)5687 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/955/II/78

Europe -DG Health and Food Safety

22-8-2018

Lenvima (Eisai Europe Limited)

Lenvima (Eisai Europe Limited)

Lenvima (Active substance: lenvatinib) - Centralised - 2-Monthly update - Commission Decision (2018)5627 of Wed, 22 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3727/II/11/G

Europe -DG Health and Food Safety

22-8-2018

BTVPUR (Merial)

BTVPUR (Merial)

BTVPUR (Active substance: Bluetongue virus vaccine (inactivated) (multistrain: 1-2 strains out of a set of 4)) - Centralised - 2-Monthly update - Commission Decision (2018)5630 of Wed, 22 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2231/II/10

Europe -DG Health and Food Safety

7-8-2018

Inovelon (Eisai Limited)

Inovelon (Eisai Limited)

Inovelon (Active substance: Rufinamide) - Centralised - 2-Monthly update - Commission Decision (2018)5424 of Tue, 07 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/660/II/45

Europe -DG Health and Food Safety

6-8-2018

Rapamune (Pfizer Limited)

Rapamune (Pfizer Limited)

Rapamune (Active substance: sirolimus) - Centralised - 2-Monthly update - Commission Decision (2018)5384 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/273/II/164

Europe -DG Health and Food Safety

6-8-2018

Dexdor (Orion Corporation)

Dexdor (Orion Corporation)

Dexdor (Active substance: dexmedetomidine) - Centralised - 2-Monthly update - Commission Decision (2018)5377 of Mon, 06 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2268/II/26

Europe -DG Health and Food Safety

3-8-2018

EU/3/18/2042 (MeiraGTx UK II Limited)

EU/3/18/2042 (MeiraGTx UK II Limited)

EU/3/18/2042 (Active substance: Adenovirus associated viral vector serotype 2/8 containing the human CNGA3 gene) - Orphan designation - Commission Decision (2018)5274 of Fri, 03 Aug 2018 European Medicines Agency (EMA) procedure number: EMA/OD/048/18

Europe -DG Health and Food Safety

1-8-2018

Eylea (Bayer AG)

Eylea (Bayer AG)

Eylea (Active substance: aflibercept) - Centralised - 2-Monthly update - Commission Decision (2018)5222 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2392/II/45

Europe -DG Health and Food Safety

1-8-2018

Opdivo (Bristol-Myers Squibb Pharma EEIG)

Opdivo (Bristol-Myers Squibb Pharma EEIG)

Opdivo (Active substance: nivolumab) - Centralised - 2-Monthly update - Commission Decision (2018)5204 of Wed, 01 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3985/II/41

Europe -DG Health and Food Safety

30-7-2018

NovoEight (Novo Nordisk A/S)

NovoEight (Novo Nordisk A/S)

NovoEight (Active substance: turoctocog alfa) - Centralised - 2-Monthly update - Commission Decision (2018)5093 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2719/II/23

Europe -DG Health and Food Safety

13-7-2018

Briviact (UCB Pharma S.A.)

Briviact (UCB Pharma S.A.)

Briviact (Active substance: brivaracetam) - Centralised - 2-Monthly update - Commission Decision (2018)4715 of Fri, 13 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3898/II/10/G

Europe -DG Health and Food Safety

9-7-2018

Pexion (Boehringer Ingelheim Vetmedica GmbH)

Pexion (Boehringer Ingelheim Vetmedica GmbH)

Pexion (Active substance: Imepitoin) - Centralised - 2-Monthly update - Commission Decision (2018)4433 of Mon, 09 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/2543/II/11/G

Europe -DG Health and Food Safety

4-7-2018

Tecentriq (Roche Registration GmbH)

Tecentriq (Roche Registration GmbH)

Tecentriq (Active substance: atezolizumab) - Centralised - 2-Monthly update - Commission Decision (2018)4336 of Wed, 04 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4143/II/10

Europe -DG Health and Food Safety

4-7-2018

Simponi (Janssen Biologics B.V.)

Simponi (Janssen Biologics B.V.)

Simponi (Active substance: golimumab) - Centralised - 2-Monthly update - Commission Decision (2018) 4350 of Wed, 04 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/992/II/79

Europe -DG Health and Food Safety

3-7-2018

Samsca (Otsuka Pharmaceutical Europe Ltd)

Samsca (Otsuka Pharmaceutical Europe Ltd)

Samsca (Active substance: tolvaptan) - Centralised - 2-Monthly update - Commission Decision (2018) 4250 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/980/II/31

Europe -DG Health and Food Safety

3-7-2018

Jinarc (Otsuka Pharmaceutical Europe Ltd)

Jinarc (Otsuka Pharmaceutical Europe Ltd)

Jinarc (Active substance: tolvaptan) - Centralised - 2-Monthly update - Commission Decision (2018)4243 of Tue, 03 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2788/II/16

Europe -DG Health and Food Safety

29-6-2018

Porcilis PCV M Hyo (Intervet International B.V.)

Porcilis PCV M Hyo (Intervet International B.V.)

Porcilis PCV M Hyo (Active substance: Porcine circovirus and Mycoplasma hyopneumoniae vaccine (inactivated)) - Centralised - 2-Monthly update - Commission Decision (2018)4166 of Fri, 29 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/3796/II/7

Europe -DG Health and Food Safety

20-6-2018

Blincyto (Amgen Europe B.V.)

Blincyto (Amgen Europe B.V.)

Blincyto (Active substance: blinatumomab) - Centralised - Authorisation - Switch to non-conditional - Commission Decision (2018)3953 of Wed, 20 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3731/II/9

Europe -DG Health and Food Safety

11-6-2018

Cimzia (UCB Pharma S.A.)

Cimzia (UCB Pharma S.A.)

Cimzia (Active substance: certolizumab pegol ) - Centralised - 2-Monthly update - Commission Decision (2018)3768 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1037/II/65

Europe -DG Health and Food Safety

11-6-2018

Cerdelga (Genzyme Europe B.V.)

Cerdelga (Genzyme Europe B.V.)

Cerdelga (Active substance: eliglustat) - Centralised - 2-Monthly update - Commission Decision (2018)3754 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3724/II/15/G

Europe -DG Health and Food Safety

11-6-2018

TAGRISSO (AstraZeneca AB)

TAGRISSO (AstraZeneca AB)

TAGRISSO (Active substance: osimertinib) - Centralised - 2-Monthly update - Commission Decision (2018)3757 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4124/II/19

Europe -DG Health and Food Safety

11-6-2018

Pradaxa (Boehringer Ingelheim International GmbH)

Pradaxa (Boehringer Ingelheim International GmbH)

Pradaxa (Active substance: dabigatran etexilate mesilate) - Centralised - 2-Monthly update - Commission Decision (2018)3755 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/829/II/108

Europe -DG Health and Food Safety

11-6-2018

Xultophy (Novo Nordisk A/S)

Xultophy (Novo Nordisk A/S)

Xultophy (Active substance: insulin degludec / liraglutide) - Centralised - 2-Monthly update - Commission Decision (2018)3779 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2647/II/23

Europe -DG Health and Food Safety

11-6-2018

Bexsero (GlaxoSmithKline Vaccines S.r.l.)

Bexsero (GlaxoSmithKline Vaccines S.r.l.)

Bexsero (Active substance: Meningococcal group B Vaccine (rDNA, component, adsorbed)) - Centralised - 2-Monthly update - Commission Decision (2018)3769 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2333/II/59

Europe -DG Health and Food Safety

6-6-2018

Prolia (Amgen Europe B.V.)

Prolia (Amgen Europe B.V.)

Prolia (Active substance: denosumab) - Centralised - 2-Monthly update - Commission Decision (2018) 3685 of Wed, 06 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/1120/II/68

Europe -DG Health and Food Safety

4-6-2018

Yervoy (Bristol-Myers Squibb Pharma EEIG)

Yervoy (Bristol-Myers Squibb Pharma EEIG)

Yervoy (Active substance: ipilimumab) - Centralised - 2-Monthly update - Commission Decision (2018)3618 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2213/II/55

Europe -DG Health and Food Safety

4-6-2018

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Bristol-Myers Squibb/Pfizer EEIG)

Eliquis (Active substance: apixaban) - Centralised - 2-Monthly update - Commission Decision (2018)3616 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2148/II/50

Europe -DG Health and Food Safety

4-6-2018

Alecensa (Roche Registration GmbH)

Alecensa (Roche Registration GmbH)

Alecensa (Active substance: alectinib) - Centralised - 2-Monthly update - Commission Decision (2018)3621 of Mon, 04 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4164/II/10

Europe -DG Health and Food Safety

15-5-2018

CABOMETYX (Ipsen Pharma)

CABOMETYX (Ipsen Pharma)

CABOMETYX (Active substance: cabozantinib) - Centralised - 2-Monthly update - Commission Decision (2018)3015 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/4163/II/3

Europe -DG Health and Food Safety

15-5-2018

Repatha (Amgen Europe B.V.)

Repatha (Amgen Europe B.V.)

Repatha (Active substance: evolocumab) - Centralised - 2-Monthly update - Commission Decision (2018)3014 of Tue, 15 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3766/II/17/G

Europe -DG Health and Food Safety

3-5-2018

Perjeta (Roche Registration GmbH)

Perjeta (Roche Registration GmbH)

Perjeta (Active substance: pertuzumab) - Centralised - 2-Monthly update - Commission Decision (2018)2771 of Thu, 03 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2547/II/35

Europe -DG Health and Food Safety

3-5-2018

Ivemend (Merck Sharp and Dohme Limited)

Ivemend (Merck Sharp and Dohme Limited)

Ivemend (Active substance: fosaprepitant) - Centralised - 2-Monthly update - Commission Decision (2018)2777 of Thu, 03 May 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/743/II/37

Europe -DG Health and Food Safety

5-3-2018

EU/3/16/1789 (La Jolla Pharmaceutical II BV)

EU/3/16/1789 (La Jolla Pharmaceutical II BV)

EU/3/16/1789 (Active substance: Synthetic human hepcidin) - Transfer of orphan designation - Commission Decision (2018)1427 of Mon, 05 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/144/16/T/02

Europe -DG Health and Food Safety

5-3-2018

EU/3/15/1555 (La Jolla Pharmaceutical II BV)

EU/3/15/1555 (La Jolla Pharmaceutical II BV)

EU/3/15/1555 (Active substance: Synthetic hepcidin) - Transfer of orphan designation - Commission Decision (2018)1426 of Mon, 05 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/092/15/T/02

Europe -DG Health and Food Safety